Adenosine Therapeutics Announces License Agreement with UVa/NIH for A2B Adenosine Receptor Blockers with Potential to Treat Asthma and Diabetes
Charlottesville, Virginia. June 1. /PRNewswire/ -- Adenosine Therapeutics, LLC, announced today that it has completed a license agreement with the University of Virginia Patent Foundation and the National Institutes of Health for approximately 50, new, A2B adenosine receptor antagonist compounds. The terms of the agreement were not disclosed. These new A2B adenosine receptor antagonist compounds have the potential to be developed in therapeutic areas that include asthma, diabetes, and retinopathy. The compounds were discovered as a result of collaboration between Kenneth A. Jacobson, Ph.D. and Joel Linden, Ph.D. Dr. Jacobson is a renowned purine chemist and head of the Molecular Recognition Section of the National Institute of Diabetes, and Digestive, and Kidney Diseases. Dr. Linden is an expert in adenosine receptor pharmacology at the University of Virginia and the Chief Scientific Officer of Adenosine Therapeutics. "These are new and important additions to Adenosine’s drug development pipeline," said Robert Capon, CEO and co-founder of Adenosine Therapeutics. "Combined with our A2A receptor agonist compounds that are already in development, they will help position us as a leading company in the identification of new candidate drugs targeting adenosine receptors." More than ten of the licensed compounds have very high affinity for recombinant human A2B receptors (KI < 5 nM) and high selectivity (> 30 fold) over the other human adenosine receptor subtypes. A prototype compound, MRS1754, has been shown to block activation by adenosine analogs of mast cells involved in asthma and allergy. Chemically, the new compounds can be described as anilide derivatives of 8-phenyxanthines and are structurally related to theophylline, which is approved to treat asthma. The use of theophylline, however, has side effects that result from blocking the A1 adenosine receptor. Radioligand binding studies with MRS1754 have shown that while it is over 3,000 times more potent than theophylline, this new compound does not block the A1 adenosine receptor. If these new compounds prove to be safe, and so far investigators have not observed any adverse affects during studies, they have clinical potential for the treatment of asthma and allergies. They also may be useful for the treatment of diabetes and retinopathy. Adenosine Therapeutics is a biotechnology company focused on the discovery and development of novel agonists and antagonists of adenosine receptor subtypes. The company's compounds that activate the A2A adenosine receptor may have applications for medical imaging and for the potential treatment of infection, ischemia-reperfusion injury, spinal cord injury, and organ transplantation.